Publications
Specialty
Search
Oncology, Journal of Clinical Pathways
07/18/2024
Results from the phase 3 MARIPOSA study found that first-line amivantamab plus lazertinib demonstrated superior efficacy compared to osimertinib among patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer.
Oncology
07/18/2024
According to results from the phase 2 NICHE-2 trial, neoadjuvant nivolumab plus ipilimumab showed promise among patients with locally advanced mismatch repair-deficient colon cancer.
Journal of Invasive Cardiology, CardioVascular
07/18/2024
The author report a case series of consecutive TAVI procedures that were considered unsuitable for the transfemoral approach after PTA failure and were consequently performed with IVL assistance.
Journal of Clinical Pathways
07/18/2024
Steve Kalloger, MSc, discusses the results from the Lymphoma Coalition’s 2022 Global Patient Survey regarding therapeutic utilization trends among patients with chronic lymphocytic leukemia (CLL).
Oncology
07/18/2024
Anthony El-Khoueiry, MD, describes data on the combination of pembrolizumab and regorafenib showed modest activity among patients with advanced hepatocellular carcinoma who had progressed on at least 1 prior immune checkpoint inhibitor regimen.
First Report Managed Care
07/18/2024
Research published in Gynecologic Oncology reveals how social determinants of health (SDOH) impact the well-being of Black and Hispanic patients who survived ovarian cancer compared to White survivors, emphasizing the need for targeted interventions to address disparities in care.
Annals of Long-Term Care
07/18/2024
“In this randomized clinical trial, acupuncture improved sleep quality and overall quality of life for individuals with PD. The therapeutic effects persisted for up to 4 weeks, underscoring the potential of acupuncture as a beneficial adjunct in managing sleep-related issues among patients with PD,” said researchers.
The Dermatologist
07/18/2024
Researchers compared the gene expression profiles of lesional and non-lesional skin biopsy tissues and the proteomic profiles of blood samples.
Neurology
07/18/2024
The calcitonin gene-related peptide inhibitor atogepant reduced monthly migraine and headache days, as well as days using pain medication, in patients with chronic migraine with and without acute medication overuse.
Vascular Disease Management, CardioVascular
07/18/2024
At the 2024 SIR Meeting in Salt Lake City, Utah, interventional radiologist Mark Lessne, MD presented several sessions, including “Beyond Paclitaxel." VDM spoke with Dr. Lessne about his presentation and the future of PAD management.
IO Learning
07/18/2024
According to the phase 3 COLLISION trial, thermal ablation for smaller colorectal liver metastases reduced morbidity and mortality without compromising survival outcomes compared to surgical resection.
Advances in Inflammatory Bowel Disease Network
07/18/2024
In part 2 of this podcast, cohost Dr Millie Long discusses her picks for the "Best of DDW" on inflammatory bowel disease with her cohost, Dr Ray Cross.
Oncology
07/17/2024
Results from the SWOG S127 study demonstrated that the addition of everolimus to endocrine therapy did not improve survival outcomes among patients with high-risk, HR-positive, early-stage breast cancer.
Pharmacy Learning Network
07/17/2024
Equibal Inc. is recalling several lots of Blemfree All Day Lotion that were manufactured without following Current Good Manufacturing Practice regulations.
Pharmacy Learning Network
07/17/2024
The recall affects Dianeal low calcium peritoneal dialysis solution.
Pulmonology
07/17/2024
Jaspal Singh, MD, MHA, MSA, discusses advances in non-invasive home mechanical ventilation, indications and benefits, and using motivational interviewing to identify the best treatment option for individual patients.
Pharmacy Learning Network
07/17/2024
Microbial contamination prompted a recall affecting 9 lots of Suntegrity Impeccable Skin Sunscreen Foundation in multiple shades.
First Report Managed Care, Population Health
07/17/2024
FY 2025 planning shows potential budget cuts for HHS and FDA, which could limit their ability to enforce regulations and address key issues.
IO Learning
07/17/2024
According to a post-hoc, exploratory analysis of safety by treatment period in the EMERALD-1 study, durvalumab plus bevacizumab plus transarterial chemoembolization had a manageable safety profile across both treatment periods among patients with embolization-eligible unresectable hepatocellular carcinoma.
Psych Congress Network
07/17/2024
Pneumonia in patients with schizophrenia is associated with the use of specific antipsychotics, according to study findings published in JAMA Psychiatry.